Liver function tests in chronic viral hepatitis cases

The liver has many vital functions and biochemical tests are usedfor the assessment. For the diagnosis of chronic hepatitis: (1)persistence of increased alanine aminotransferase (ALT) for 6months after an episode of acute hepatitis; or (2) increased ALT(without another explanation) on more than one occasion over aperiod of 6 months are needed. The time period may be shorter forthe patients with risk factors. Although the clinical picture of HBVand HCV in chronic cases is similar, aminotransferase activitiesare different. In HBV, ALT activity is generally constant, exceptincreases are evident at seroconversion times. On the other hand,two-third of HCV cases experience fluctuation. In the evaluationof a patient with a new diagnosis of chronic viral hepatitis, acomprehensive medical history should be taken, followed byfull physical examination. Laboratory workup should start with acomprehensive metabolic panel with liver function tests includingassessment of synthetic function with prothrombin time and serumalbumin level measurement. Screening for the chronic hepaticinjury is not cost-effective and should be limited to high-riskindividuals. ALT should be the preferred biochemistry parameterbesides viral serology and increased activity should be confirmedbefore further evaluation. For treatment, patients with increasedALT are more likely to respond than those with initially normalALT activity.Keywords: Chronic viral hepatitis, Hepatitis B virus, Hepatitis Cvirus, Alanine aminotransferase, Aspartate aminotransferase

Anahtar Kelimeler:

Kronik viral hepatit, Hepatit B virüsü, Hepatit C virüsü, Alanin aminotransferaz, Aspartat aminotransferaz

Liver function tests in chronic viral hepatitis cases

PDF

___

Burtis CA, Ashwood ER, Bruns D (editors). Tietz Textbook
of Clinical Chemistry and Molecular Medicine. St. Louis
Elsevier Saunders, 2006: 1777-847.
Dufour D, Lott J, Nolte F, et al. Diagnosis and monitoring
of hepatic injury. II. Recommendations for use of laboratory
tests in screening, diagnosis, and monitoring. Clin Chem
46:2050-68.
Dincer D, Okten A, Kaymakoglu S, et al. Persistantly normal
alanine transaminase levels in chronic C hepatitis: What does
it tell us? Hepatogastroenterology 2001;48:1397-400.
Mofrad P, Contos M, Haque M, et al. Clinical and histologic
spectrum of nonalcoholic fatty liver disease associated with
normal ALT values. Hepatology 2003;37:1286-92.
Dufour DR. Alanine aminotransferase variation in chronic
hepatitis C infection: An analysis of 357 cases. Clin Chem
47:A26-A7.
Alter HJ, Conry-Cantilena C, Melpolder J, et al. Hepatitis C
in asymptomatic blood donors. Hepatology 1997;26(Suppl
29–33.
Mathurin P, Moussalli J, Cadranel J-F, et al. Slow progression
rate of fibrosis in hepatitis C patients with persistently normal
alanine aminotransferase activity. Hepatology 1998;27:568–
Inglesby TV, Rai R, Astemborski J, et al. A prospective
community-based evaluation of liver enzymes in individuals
with hepatitis C after drug use. Hepatology 1999;29:590–6.
Kenny-Walsh E. Clinical outcomes after hepatitis C infection
from contaminated anti-D immune globulin. The Irish
Hepatology Research Group. N Engl J Med 1999;340:1228–
Hoofnagel JH. Hepatitis C: the clinical spectrum of disease.
Hepatology 1997;26(Suppl 1):15–20.
Chang C, Ko Y, Liu H. Serum alanine aminotransferase
levels in relation to hepatitis B and C virus infections among
drug abusers in an area hyperendemic for hepatitis B. Dig
Dis Sci 2000;45:1949-52.
Fontana R, Lok A. Noninvasive monitoring of patients with
chronic hepatitis C. Hepatology 2002;36:S57-64.
Imperiale T, Said A, Cummings O, Born L. Need for
validation of clinical decision aids: Use of the AST/ALT
ratio in predicting cirrhosis in chronic hepatitis C. Am J
Gastroenterol 2000;95:2328-32.
Park G, Lin B, Ngu M, Jones D, Kateralis P. Aspartateaminotransferase: alanine aminotransferase ratio in chronic
hepatitis C infection: Is it a useful predictor of cirrhosis? J
Gastroenterol Hepatol 2000;15:386-90.
Sheth SG, Glamm SL, Gordon FD, Chopra S. AST/ALT ratio
predicts cirrhosis in patients with chronic hepatitis C virus
infection. Am J Gastroenterol 1998;93:44-8.
Giannini E, Botta F, Fasoli A, et al. Progressive liver
functional impairment is associated with an increase in AST/
ALT ratio. Dig Dis Sci 1999;44:1249–53.
Friedman LS, Dienstag JL, Watkins E, et al. Evaluation of
blood donors with elevated serum alanine aminotransferase
levels. Ann Intern Med 1987; 107:137-44.
Hay JE, Czaja AJ, Rakela J, Ludwig J. The nature of
unexplained chronic aminotransferase elevations of a mild
to moderate degree in asymptomatic patients. Hepatology
9:193-7.
McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren
MH. Evaluation of liver histology, ALT elevation, and
HCV RNA titer in patients with chronic hepatitis C. Am J
Gastroenterol 1996; 91:1516-22.
Gobel T, Erhardt A, Herwig M, et al. High prevalence of
significant liver fibrosis and cirrhosis in chronic hepatitis
B patients with normal ALT in central Europe. J Med Virol
83:968-73.
Lu SN, Wang JH, Liu SL, et al. Thrombocytopenia as a
surrogate for cirrhosis and a marker for the identification of
patients at high-risk for hepatocellular carcinoma. Cancer
107:2212-22.
Wai CT, Greenson JK, Fontana RJ, et al. A simple
noninvasive index can predict both significant fibrosis and
cirrhosis in patients with chronic hepatitis C. Hepatology
38:518-26.
Forns X, Ampurdanes S, Llovet JM, et al. Identification of
chronic hepatitis C patients without hepatic fibrosis by a
simple predictive model. Hepatology 2002; 36(4 Pt 1):986-
Bitetto D, Fattovich G, Fabris C, et al. Complementary role
of vitamin D deficiency and the interleukin-28B rs12979860
C/T polymorphism in predicting antiviral response in chronic
hepatitis C. Hepatology 2011; 53:1118-26.
Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D
deficiency and a CYP27B1–1260 promoter polymorphism
are associated with chronic hepatitis C and poor response to
interferon-alfa based therapy. J Hepatol 2011; 54:887-93.
Petta S, Camma C, Scazzone C, et al. Low vitamin D serum
level is related to severe fibrosis and low responsiveness to
interferon-based therapy in genotype 1 chronic hepatitis C.
Hepatology 2010; 51:1158-67.
Brau N. Evaluation of the Hepatitis C Virus–Infected Patient
The Initial Encounter. Viral Hepatitis 2013;56:853-60.
Kamath PS, Wiesner RH, Malinchoc M, et al. A model to
predict survival in patients with end-stage liver disease.
Hepatology 2001; 33: 464-70.
EASL Clinical Practice Guidelines. Manage- ment of chronic
hepatitis B. Association for the Study of the Liver. J Hepatol
57:167-185.
ChanHL, WongGL, WongVW. A review of the natural history
of chronic hepatitis B in the era of transient elastography.
Antivir Ther 2009;14:489-99.
Sharifi Z. Natural history of chronic hepatitis B virus
infection based on laboratory testing. Iranian J Publ Health
7:990-3.
Recommendations for the identification of chronic hepatitis
C virus infection among persons born during 1945-1965.
MMWR Recomm Rep 2012; 61(RR-4):1–32.
David T Arnold DT, Bentham LM, Jacob RP, Lilford RJ
Girling AJ. Should patients with abnormal liver function
tests in primary care be tested for chronic viral hepatitis: cost
minimisation analysis based on a comprehensively tested
cohort. BMC Family Practice 2011; 12:9-22.
Heidelbaugh JJ, Bruderly AM. Cirrhosis and Chronic Liver
Failure: Part I. Diagnosis and Evaluation. Am Fam Physician
74: 756-62.
Van Ness MM, Diehl AM. Is liver biopsy useful in the
evaluation of patients with chronically elevated liver
enzymes? Ann Intern Med 1989;111:473–8.
Kundrotas LW, Clement DJ. Serum alanine aminotransferase
(ALT) elevation in asymptomatic US Air Force basic trainee
blood donors. Dig Dis Sci 1993;38:2145-50.
de Franchis R, Meucci G, Vecchi M, et al. The natural history
of asymptomatic hepatitis B surface antigen carriers. Ann
Intern Med 1993;118:191-4.
Lok AS, Ghany MG, Watson G, Ayola B. Predictive value
of aminotransferase and hepatitis B virus DNA levels on
response to interferon therapy for chronic hepatitis B. J Viral
Hepat 1998;5:171-8.
Lai CL, Chien RN, Leung NW, et al. A one-year trial
of lamivudine for chronic hepatitis B. N Engl J Med
339:61-8.